rabbit polyclonal anti cd206 antibody  (Proteintech)

Journal: PLOS One

Article Title: TNFAIP3 alleviates cerebral ischemia-reperfusion injury by inhibiting M1 microglia polarization via deubiquitination of RACK1

doi: 10.1371/journal.pone.0337601

Figure Lengend Snippet: (A) Quantitative analysis of iNOS protein levels; (B) Quantitative analysis of CD16/32 protein levels; (C) Quantitative analysis of Arg-1 protein levels; (D) Quantitative analysis of CD206 protein levels. (E-F) Flow cytometry (FCM) analysis of the proportion of CD16/32 + cells in the different experimental groups; (G-H) FCM analysis of the proportion of CD206 + cells in the different experimental groups. Data are presented as the mean ± SD from replicate experiments (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001. The endpoints of the line segment indicate the comparison between the two groups under consideration.

Article Snippet: Subsequently, cells were incubated with 3% BSA for 30 min at 37°C to block non-specific binding, and then exposed to primary antibodies at 4°C overnight, including anti-CD206 rabbit polyclonal antibody (1:100; cat. no. DF4149; Affinity Biosciences) and anti-CD16/32 (1:500; cat. no. ab223200; Abcam).

Techniques: Flow Cytometry, Comparison

Journal: PLOS One

Article Title: TNFAIP3 alleviates cerebral ischemia-reperfusion injury by inhibiting M1 microglia polarization via deubiquitination of RACK1

doi: 10.1371/journal.pone.0337601

Figure Lengend Snippet: (A-B) Representative images of double immunostaining and quantitative analysis of BV2 microglial M1 polarization, with CD16/32 (red) and DAPI (green); Scale bar = 100 μm. (C-D) Representative images of double immunostaining and quantitative analysis of BV2 microglial M1 polarization, with CD206 (red) and DAPI (green); Scale bar = 100 μm. Data are presented as the mean ± SD from replicate experiments (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001. The endpoints of the line segment indicate the comparison between the two groups under consideration.

Article Snippet: Subsequently, cells were incubated with 3% BSA for 30 min at 37°C to block non-specific binding, and then exposed to primary antibodies at 4°C overnight, including anti-CD206 rabbit polyclonal antibody (1:100; cat. no. DF4149; Affinity Biosciences) and anti-CD16/32 (1:500; cat. no. ab223200; Abcam).

Techniques: Double Immunostaining, Comparison

Journal: PLOS One

Article Title: TNFAIP3 alleviates cerebral ischemia-reperfusion injury by inhibiting M1 microglia polarization via deubiquitination of RACK1

doi: 10.1371/journal.pone.0337601

Figure Lengend Snippet: (A) Quantitative analysis of iNOS protein levels; (B) Quantitative analysis of CD16/32 protein levels; (C) Quantitative analysis of Arg-1 protein levels; (D) Quantitative analysis of CD206 protein levels. (E-F) Flow cytometry (FCM) analysis of the proportion of CD16/32 + cells in the different experimental groups; (G-H) FCM analysis of the proportion of CD206 + cells in the different experimental groups. Data are presented as the mean ± SD from replicate experiments (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001. The endpoints of the line segment indicate the comparison between the two groups under consideration.

Article Snippet: Subsequently, cells were incubated with 3% BSA for 30 min at 37°C to block non-specific binding, and then exposed to primary antibodies at 4°C overnight, including anti-CD206 rabbit polyclonal antibody (1:100; cat. no. DF4149; Affinity Biosciences) and anti-CD16/32 (1:500; cat. no. ab223200; Abcam).

Techniques: Flow Cytometry, Comparison

Journal: PLOS One

Article Title: TNFAIP3 alleviates cerebral ischemia-reperfusion injury by inhibiting M1 microglia polarization via deubiquitination of RACK1

doi: 10.1371/journal.pone.0337601

Figure Lengend Snippet: (A-B) Representative images of double immunostaining and quantitative analysis of BV2 microglial M1 polarization, with CD16/32 (red) and DAPI (green); Scale bar = 100 μm. (C-D) Representative images of double immunostaining and quantitative analysis of BV2 microglial M1 polarization, with CD206 (red) and DAPI (green); Scale bar = 100 μm. Data are presented as the mean ± SD from replicate experiments (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001. The endpoints of the line segment indicate the comparison between the two groups under consideration.

Article Snippet: Subsequently, cells were incubated with 3% BSA for 30 min at 37°C to block non-specific binding, and then exposed to primary antibodies at 4°C overnight, including anti-CD206 rabbit polyclonal antibody (1:100; cat. no. DF4149; Affinity Biosciences) and anti-CD16/32 (1:500; cat. no. ab223200; Abcam).

Techniques: Double Immunostaining, Comparison

Journal: PLOS One

Article Title: TNFAIP3 alleviates cerebral ischemia-reperfusion injury by inhibiting M1 microglia polarization via deubiquitination of RACK1

doi: 10.1371/journal.pone.0337601

Figure Lengend Snippet: (A) Quantitative analysis of iNOS protein levels; (B) Quantitative analysis of CD16/32 protein levels; (C) Quantitative analysis of Arg-1 protein levels; (D) Quantitative analysis of CD206 protein levels. (E-F) Flow cytometry (FCM) analysis of the proportion of CD16/32 + cells in the different experimental groups; (G-H) FCM analysis of the proportion of CD206 + cells in the different experimental groups. Data are presented as the mean ± SD from replicate experiments (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001. The endpoints of the line segment indicate the comparison between the two groups under consideration.

Article Snippet: Subsequently, cells were incubated with 3% BSA for 30 min at 37°C to block non-specific binding, and then exposed to primary antibodies at 4°C overnight, including anti-CD206 rabbit polyclonal antibody (1:100; cat. no. DF4149; Affinity Biosciences) and anti-CD16/32 (1:500; cat. no. ab223200; Abcam).

Techniques: Flow Cytometry, Comparison

Journal: bioRxiv

Article Title: Siglec-engaging immunosuppressive sialoglycans are upregulated in prostate cancer and are targetable to suppress bone metastasis

doi: 10.1101/2025.11.12.687981

Figure Lengend Snippet: Dot plots of Siglec gene expression levels at single cell resolution in prostate tumours using previously published single cell RNA-sequencing data from ( A ) primary prostate tumours and ( B ) prostate cancer bone metastatic tissues . ( C ) Dual immunofluorescence analysis of Siglec receptors and immune cell markers in independent prostate cancer bone metastasis tissue samples. This analysis was also carried out for primary prostate tissue (Supplementary Figure 4). Siglec-7, -9, -10 and -15 are co-expressed with CD14 (a myeloid marker) and CD206 (an M2 macrophage marker) in bone metastatic tumours. Furthermore, we reveal Siglec-3 and -15 are expressed with cathepsin K (an osteoclast marker). Scale bar is 20□µm.

Article Snippet: Tissues were then blocked with 1X CFB for 1 hr at room temperature, following overnight incubation in the dark at 4 °C in 1:400 CD22 Monoclonal Antibody (Proteintech, 66103-1-Ig), 1:200 Anti-CD33 Antibody [WM53] (Abcam, ab252263), 1:200 Siglec-7/CD328 Polyclonal Antibody (Proteintech, 13939-1-AP), 1:200 Siglec-9 Polyclonal Antibody (Proteintech, 13377-1-AP), 1:100 Siglec-10 Polyclonal Antibody (Invitrogen, PA5-55501), 1:100 Siglec-15 Polyclonal Antibody (Abcam, ab198684), 1:50 Mouse Siglec-E Antibody (R&D Systems, AF5806), 1:200 CD14 Rabbit Polyclonal Antibody (Proteintech, 17000-1-AP), 1:200 CD14 Mouse Monoclonal Antibody (Proteintech, 60253-1-Ig), 1:500 AMACR/p504S Rabbit Polyclonal Antibody (Proteintech, 15918-1-AP), 1:200 AMACR Mouse Monoclonal Antibody [UMAB68] (UltraMAB, UM870012), 1:200 CD206 Rabbit Polyclonal Antibody (Proteintech, 18704-1-AP), 1:200 CD206 Mouse Monoclonal Antibody (Proteintech, 60143-1-Ig), 1:200 Cathepsin K Rabbit Polyclonal Antibody (Proteintech, 11239-1-AP), 1:200 Cathepsin K Mouse Monoclonal Antibody [E-7] (Santa Cruz, sc-48353), 1:200 CD20 Rabbit Polyclonal Antibody (Proteintech, 24828-1-AP) or 1:100 Pan Cytokeratin Monoclonal Antibody (AE1/AE3), Alexa FluorTM 488-conjugated (Invitrogen 53-9003-80).

Techniques: Gene Expression, RNA Sequencing, Immunofluorescence, Marker